Clinical Trial Update: Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE [Phase 1, Phase 2]

View source ↗

Summary

Phase 1b/2a study evaluating safety and efficacy of KPG-818 in systemic lupus erythematosus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• KPG-818

Snippet

Sponsor: Kangpu Biopharmaceuticals, Ltd. | Conditions: SLE; Drug | Phase 1, Phase 2 | Status: COMPLETED